investors & media

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Copyright West LLC. Minimum 15 minutes delayed.

press releases

8/22/2019

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 22, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14 th Annual Biotech Conference , Wednesday, September 4 , at 8:00 a.m.

Read more
8/1/2019

– Received EU conditional marketing authorization for ZYNTEGLO ® (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion dependent β-thalassemia (TDT) who do not have a β 0 /β 0 genotype – – Presented data across LentiGlobin® for TDT and

Read more
6/14/2019

Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT who do not have a β 0 /β

Read more